- Home
- SGRY vs PVLA Comparison
SGRY vs PVLA Comparison
Compare SGRY & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGRY | PVLA |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | SGRY | PVLA |
|---|---|---|
| Price | $13.69 | $117.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 15 |
| Target Price | $22.25 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 1.6M | 175.2K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,145,438,000.00 | N/A |
| Revenue This Year | $5.09 | N/A |
| Revenue Next Year | $5.67 | $104,350.18 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.41 | $20.20 |
| 52 Week High | $24.10 | $151.18 |
Technical Indicators
Market Signals| Indicator | SGRY | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 49.02 | 48.38 |
| Support Level | $13.35 | $109.68 |
| Resistance Level | $14.94 | $135.23 |
| Average True Range (ATR) | 0.50 | 5.65 |
| MACD | -0.07 | 0.08 |
| Stochastic Oscillator | 41.06 | 60.00 |
Price Performance
Historical ComparisonAbout SGRY Surgery Partners Inc.
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.